Exogenesis COVID-19 Deactivation Challenge Trial Reaches Primary Endpoints

October 16, 2020

Exogenesis COVID-19 Deactivation Challenge Trial Reaches Primary Endpoints

Exogenesis Corporation announced that it had acheived the primary endpoints of trapping and deactivating SARS-CoV-2 in simulated real-world exposures in a series of challenge tests for the Exogenesis Surgical Mask (ESM), a protective nose and mouth covering for healthcare workers and patients involved in medical and surgical procedures. Any innovation that enhances patient and clinician safety is welcome news to Yourway and our clients trying to conduct clinical trials during the pandemic.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Pharma Supply Chain & Logistics Innovation Programme EU

May 20-21, 2026
Basel, Switzerland

Schedule a Meeting

Clinical Trial Supply West Coast

September 22-23, 2026
Burlingame, CA

Schedule a Meeting

Media

Articles

Maintaining Temperature Integrity in Direct-to-Patient Clinical Trials

Open chat

Hello! How can I help you?